Astragaloside IV Improves Diabetic Kidney Disease by Regulating NLRP3 Inflammasome
Journal of Diabetes Research · 2025-01 · 2025 (1)
DOI: 10.1155/jdr/3340719 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Diabetes Research, online erschienen am 30.11.2025. Verfasst von Han Zhu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Saponins, Diabetic Nephropathies, Triterpenes. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Science and Technology Planning Project, National Natural Science Foundation of China.
Abstract (Originalsprache)
Diabetic kidney disease (DKD) is a chronic complication that seriously affects the prognosis of diabetic patients and is a primary reason for end‐stage renal disease worldwide. The existing treatment strategies have shown unsatisfactory results in the clinical practice of DKD, and there is an immediate need to discover novel and efficacious medicines. Natural products are considered to have the potential for drug design and development due to their diverse pharmacological effects. Astragaloside IV (AS‐IV) has a variety of biological activities as a natural product, and existing studies have demonstrated that it can effectively delay the progression of DKD through multiple pathways. Aseptic inflammation is a key characteristic of DKD and is crucial in its pathogenesis. Nucleotide‐binding oligomerization domain‐like receptor protein 3 (NLRP3) inflammasome is an essential regulator of inflammatory amplification. In this review, we focus on the mechanisms by which AS‐IV improves DKD by regulating NLRP3 inflammasome activation, including anti‐inflammatory, antioxidative stress, reducing endoplasmic reticulum stress (ERS), regulating lipid metabolism disorders, and reducing pyroptosis. These discoveries have provided new ideas for the treatment of DKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China.
- Institute of Basic Theory for Chinese Medicine, China Academy of Chinese Medical Sciences, Beijing, China.
- Institute of Clinical Pharmacology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
- NMPA Key Laboratory for Clinical Research and Evaluation of Traditional Chinese Medicine, Beijing, China.
- Beijing Engineering Research Center of Printed Electronics, Beijing Institute of Graphic Communication, Beijing, China.
- Department of Nephrology, Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang, Jiangxi, China.
ORCID-Profile: Han Zhu, Wantong Zhang, Lu Han, Yong Huang
Förderung
- Beijing Science and Technology Planning Project
- National Natural Science Foundation of China
Zitieren
APA
Zhu, H., Zheng, L., Zhao, K., Wang, X., Ma, Z., Zeng, A., Zhao, W., Zhang, W., Han, L., & Huang, Y. (2025). Astragaloside IV Improves Diabetic Kidney Disease by Regulating NLRP3 Inflammasome. Journal of Diabetes Research, 2025(1). https://doi.org/10.1155/jdr/3340719
Vancouver
Zhu H, Zheng L, Zhao K, Wang X, Ma Z, Zeng A, et al. Astragaloside IV Improves Diabetic Kidney Disease by Regulating NLRP3 Inflammasome. Journal of Diabetes Research. 2025;2025(1). doi:10.1155/jdr/3340719
BibTeX
@article{Zhu2025,
author = {Zhu, Han and Zheng, Liping and Zhao, Keqin and Wang, Xin and Ma, Zeming and Zeng, Ao and Zhao, Weijie and Zhang, Wantong and Han, Lu and Huang, Yong},
title = {Astragaloside IV Improves Diabetic Kidney Disease by Regulating NLRP3 Inflammasome},
journal = {Journal of Diabetes Research},
year = {2025},
volume = {2025},
number = {1},
doi = {10.1155/jdr/3340719}
}
EUVIMED